Navigation Links
University of Glasgow Becomes a Member of GeneGo's MetaMiner Stem Cell Partnership Program
Date:1/27/2009

ST. JOSEPH, Mich., Jan. 27 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Professor Nicol Keith of the University of Glasgow will join the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for Adult, Embryonic, Fetal, Fibroblasts, Hematopoietic, Mesenchymal, Multipotent, Neoplastic, Pluripotent and Totipotent stem cells.

"We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps," said Nicol Keith, Professor of Molecular Oncology. "This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly."

"Professor Nicol Keith, of the University of Glasgow in Scotland is world renowned for his pioneering work in cellular immortality and we are pleased to have him on our team," said Julie Bryant, GeneGo's VP of Business Development. "We have a lot of experience at building pathway maps and we plan to have 10 types of stem cell pathway maps completed in 24 months."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers
2. University of Helsinki and ASM International renew research agreement on atomic layer deposition
3. Cell Biosciences Delivers Next Generation System to Stanford University
4. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
5. University of Minnesota Receives $40 Million for Type 1 Diabetes Research
6. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
7. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
8. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
9. University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
10. Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman
11. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a ... technology for research and clinical applications. The terms of the transaction were not ...
(Date:2/22/2017)... Scientists propose in Nature blocking a molecule ... maybe other lysosomal storage diseases as a possible treatment ... An international research team led by ... investigators from the University of L├╝beck in ... study was conducted in mouse models of lysosomal storage ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is pleased to announce ... February 22 and 23, 2017. This premier, online-only conference focused on the development ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):